Time for Poilievre to join a constructive pharmacare conversation
Green Party Leader Elizabeth May and NDP Leader Jagmeet Singh have done their part as responsible opposition critics on this policy. Now it’s Pierre Poilievre’s turn.
Equity must be the priority for national pharmacare
Canadians have the chance to consider whether to view access to medicines as a pillar of healthcare, or simply an add-on service.
Pharmacare pivotal to ensure vital medications for all Canadians: CML Society of Canada
Re: “First phase of pharmacare must not ‘create new gaps’ in existing coverage, says lobbyists (The Hill Times, April 1). I strongly endorse the Pharmacare Act as a pivotal measure to ensure universal access to vital medications for all Canadians. Its multi-faceted approach—including collaboration, policy development, and strategic initiatives such as national pharmacare and bulk […]
A national pharmacare plan should cover what’s best for patients, not what’s new
Using insulin is always challenging, so access to a broad range of appropriate options is vital.
First phase of pharmacare must not ‘create new gaps’ in existing coverage, say lobbyists
Bill C-64 outlines a proposed first phase towards implementation of national universal pharmacare to address accessibility and affordability of prescription drugs and related products.
Trudeau’s pharmacare plan would likely reduce drug coverage for millions of Canadians
The proposed new law would likely prohibit Canadians from purchasing supplemental insurance to cover drugs not covered (or only partially covered) by pharmacare.
Trudeau government not being honest about true costs of national pharmacare
The government will likely need to borrow to finance any new spending and add more debt, which will result in higher taxes in the future. And yet, pharmacare is being presented to Canadians as if there’s no direct cost to them.
Florida importation program won’t cause drug shortages in Canada: state secretary
Florida’s plan is designed to relieve pressure on an already overburdened government health-care system, and will bring tens, if not hundreds, of millions of dollars in new business to Canada.
FDA approval may spell trouble for Canadian patients
The FDA’s Florida decision might wind up limiting Canadians’ access to pharmaceutical medicines as long as Canadian drug prices remain well below prices in the United States.
Global trade disruptions and election fever contribute to ‘unpredictable’ 2024 for advocacy, say lobbyists
Pharmacare and Bill C-234, an act to amend the Greenhouse Gas Pollution Pricing Act, are likely to be top issues for government relations this year.
